News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Volasertib, Boehringer Ingelheim Corporation´s Investigational Treatment Of Acute Myeloid Leukaemia, Is Granted "Orphan Drug Designation" In The EU And The U.S.


4/17/2014 9:42:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US and UK only. Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* ‘orphan drug designation’ for the treatment of patients with acute myeloid leukaemia (AML).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES